AKBA
Akebia Therapeutics, Inc.
0.865$
-0.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 2,178.2% | 287.8% | 153.4% | 142.2% | 78.3% | 133.7% | 147.4% | 132.8% | 12.8% | 43.0% | 37.4% | 41.6% | 14.4% | 31.3% | 193.7% | 50.6% | 47.3% | 66.2% | 99.2% | 32.7% | 55.0% | 50.8% | 14.7% | 78.6% | -5.6% | 50.5% | 30.7% | 42.8% | 33.2% | 8.3% | 19.0% | 37.8% | 43.8% | 13.3% | 15.9% | 16.5% | 21.2% | 23.6% | 21.2% | 20.5% | |
| – | -2,078.2% | -187.8% | -53.4% | -42.2% | 21.7% | -33.7% | -47.4% | -32.8% | 87.2% | 57.0% | 62.6% | 58.4% | 85.6% | 68.7% | -93.7% | 49.4% | 52.7% | 33.8% | 0.8% | 67.3% | 45.0% | 49.2% | 85.3% | 21.4% | 105.6% | 49.5% | 69.3% | 57.2% | 66.8% | 91.7% | 81.0% | 62.2% | 56.2% | 86.7% | 84.1% | 83.5% | 78.8% | 76.4% | 78.8% | 79.5% | |
| – | 2,178.2% | 287.8% | 153.4% | 142.2% | 78.3% | 133.7% | 147.4% | 132.8% | 145.6% | 113.3% | 85.0% | 81.0% | 115.6% | 91.8% | 58.6% | 78.1% | 66.3% | 77.6% | 70.3% | 83.0% | 51.2% | 71.0% | 20.6% | 57.5% | 57.8% | 49.2% | 35.8% | 31.7% | 17.6% | 29.8% | 17.5% | 22.7% | 25.3% | 17.0% | 17.6% | 24.9% | 46.2% | 27.7% | 28.6% | 32.0% | |
| – | 400.3% | 27.7% | 24.2% | 16.3% | 8.7% | 19.6% | 25.7% | 19.5% | 92.2% | 48.2% | 36.7% | 38.2% | 56.0% | 43.7% | 40.5% | 68.1% | 62.3% | 80.3% | 80.4% | 96.9% | 63.5% | 73.0% | 26.7% | 65.0% | 42.1% | 0.4% | 48.0% | 54.0% | 1.5% | 78.0% | 61.7% | 70.8% | 49.6% | 44.9% | 42.5% | 49.5% | 45.3% | 56.8% | 57.3% | 51.9% | |
| – | 2,578.4% | 315.5% | 177.6% | 158.6% | 87.0% | 153.3% | 173.1% | 152.4% | 237.8% | 161.5% | 121.7% | 119.2% | 222.0% | 135.5% | 99.1% | 146.3% | 203.3% | 158.0% | 150.7% | 179.9% | 158.3% | 144.0% | 58.3% | 124.9% | 117.1% | 113.5% | 85.3% | 88.2% | 64.3% | 137.5% | 101.0% | 95.6% | 87.0% | 63.1% | 61.6% | 75.9% | 93.6% | 85.2% | 91.7% | 86.4% | |
| – | -2,478.4% | -215.5% | -77.6% | -58.6% | 13.0% | -53.3% | -73.1% | -52.4% | -150.6% | -104.5% | -59.0% | -60.8% | -136.4% | -66.8% | -192.8% | -96.8% | -150.6% | -124.2% | -149.9% | -112.6% | -113.3% | -94.8% | 27.0% | -103.5% | -11.5% | -64.0% | -16.0% | -31.0% | 2.4% | -45.8% | -20.0% | -33.4% | -30.8% | 23.6% | 22.6% | 7.6% | -14.8% | -8.8% | -12.9% | -6.9% | |
| – | 11.7% | 2.1% | 2.1% | 2.0% | 1.0% | 2.3% | 3.2% | 3.3% | 2.9% | 1.2% | 0.5% | 0.2% | 1.1% | 2.2% | 2.6% | 3.8% | 4.1% | 9.2% | 9.4% | 10.4% | 8.8% | 8.2% | 4.0% | 8.1% | 3.0% | 3.9% | 2.9% | 3.4% | 2.5% | 7.7% | 4.9% | 17.8% | 14.8% | 13.6% | 10.9% | 8.1% | 8.4% | 8.8% | 6.3% | 7.9% | |
| – | -2,466.6% | -213.5% | -75.4% | -56.0% | 14.1% | -51.0% | -69.8% | -49.0% | -147.7% | -103.5% | -58.5% | -60.7% | -133.3% | -68.7% | -195.0% | -100.0% | -153.4% | -133.0% | -156.9% | -122.1% | -121.1% | -101.2% | 23.3% | -111.0% | -13.7% | -67.2% | -19.8% | -34.5% | 1.1% | -55.2% | -19.7% | -53.5% | -49.0% | 10.7% | 0.4% | 2.0% | -19.5% | -16.7% | -18.0% | -12.7% | |
| – | -11.7% | -2.1% | -2.1% | -2.0% | 0.0% | -2.3% | -3.2% | -3.3% | -47.3% | -3.8% | -0.8% | -1.4% | 2.5% | 2.6% | 2.6% | 4.5% | -13.6% | 9.5% | 11.8% | 11.3% | -8.8% | 6.4% | 3.7% | 7.9% | 2.2% | -23.7% | 0.2% | 3.3% | 0.0% | 28.6% | – | – | – | – | – | 1.0% | 1.8% | 0.2% | 0.1% | 0.8% | |
| – | -2,466.6% | -213.5% | -75.4% | -56.0% | 14.1% | -51.0% | -69.8% | -49.0% | -147.7% | -99.7% | -57.7% | -59.3% | -135.8% | -68.7% | -195.0% | -100.0% | -153.4% | -133.0% | -156.9% | -122.1% | -121.1% | -101.2% | 23.3% | -111.0% | -13.7% | -67.2% | -19.8% | -34.5% | 1.1% | -55.2% | -19.7% | -53.5% | -49.0% | 10.7% | 0.4% | 0.9% | -21.2% | -16.9% | -18.1% | -13.5% | |
| – | -2,470.4% | -214.9% | -77.2% | -58.2% | 13.2% | -52.9% | -72.6% | -51.9% | -144.8% | -90.3% | -48.9% | -50.2% | -93.8% | -55.6% | -181.7% | -85.1% | -83.8% | -105.6% | -130.5% | -92.2% | -83.2% | -77.7% | 34.8% | -83.6% | 31.2% | -39.8% | -0.2% | -8.7% | 20.4% | -15.1% | 2.7% | -10.7% | -14.2% | 24.8% | 11.8% | 10.6% | -10.6% | -24.8% | -9.9% | -8.2% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.